Freedman Jacob, Nilsson Henrik, Jonas Eduard
Karolinska Institutet, Department of Clinical Sciences, Division of Surgery, Danderyd Hospital, 182 88 Stockholm, Sweden.
Clintec, Karolinska Institute, Department of Surgery, Karolinska University Hospital, Stockholm, Sweden.
Hepat Oncol. 2015 Oct;2(4):349-358. doi: 10.2217/hep.15.28. Epub 2015 Nov 6.
Historically ablative treatment for hepatocellular cancer (HCC) has been regarded as inferior to transplantation and resection and has therefore been reserved for patients not suitable for surgical intervention in stage 0-A HCC according to the Barcelona Clinic Liver Cancer classification system. In the wake of surgical strategies challenging the current Barcelona Clinic Liver Cancer treatment guidelines and improvements in imaging, targeting and ablation technologies, ablation is likely to occupy a more central role in the management of patients with HCC, challenging its historically perceived inferiority to resection.
从历史上看，肝细胞癌（HCC）的消融治疗一直被认为不如移植和切除，因此，根据巴塞罗那临床肝癌分类系统，它一直被保留用于0-A期HCC中不适合手术干预的患者。随着手术策略对当前巴塞罗那临床肝癌治疗指南的挑战以及成像、靶向和消融技术的改进，消融在HCC患者的管理中可能会占据更核心的地位，挑战其在历史上被认为不如切除的地位。
